Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

255.34 -3.16 (-1.22%)
Streaming Delayed Price Updated: 11:53 AM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens. 
Via Benzinga
News headline image
These 3 Beaten-Down Stocks Haven't Been This Cheap in Over a Decade ↗
Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns. 
Via The Motley Fool
Topics Economy World Trade
News headline image
This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market ↗
The company is a picture of financial stability. 
Via The Motley Fool
News headline image
Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector ↗
Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors. 
Via The Motley Fool
Topics Regulatory Compliance
Johnson & Johnson (NYSE:JNJ) Stands Out as a Quality Dividend Stock for Reliable Income ↗
Via Chartmill
News headline image
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
From Johnson & Johnson
Via Business Wire
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Could this player be heading into a new era of growth? 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that... 
Via MarketMinute
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,... 
Via MarketMinute
News headline image
Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗
The answer to the question might surprise many investors. It pays to be open-minded about risk. 
Via The Motley Fool
Topics Economy Energy
News headline image
JEPI vs. JEPQ: Which Is the Better Buy in April? ↗
These two high-yield heavyweights offer very different approaches. 
Via The Motley Fool
Topics Bonds ETFs Economy
News headline image
Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?
Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now. 
Via Barchart.com
News headline image
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided... 
Via MarketMinute
Topics Economy Retirement
News headline image
This Healthcare Stock Barely Flinches During Market Sell-Offs ↗
Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm ↗
These blue-chip stocks can make investors money if stagflation returns -- and also if it doesn't. 
Via The Motley Fool
Topics Economy
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Volatility Is Spiking. Here Are 3 Dividend Stocks You Can Buy Without Hesitation. ↗
These dividend stocks are ones you can rest peacefully at night owning. 
Via The Motley Fool
Topics Economy
News headline image
The Dividend King That's Raised Its Payout for 63 Consecutive Years ↗
This healthcare leader can weather almost any storm. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Deep Dive: Boston Scientific (BSX) and the New Era of Medical Device Dominance
Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its... 
Via Finterra
Topics Lawsuit Product Recall
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Eli Lilly is much more than just a weight loss stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Intuitive Surgical a Buy Right Now? ↗
The healthcare leader has seen better times. 
Via The Motley Fool
Topics World Trade
News headline image
2 Stocks I Plan to Hold for the Next 20 Years ↗
These companies help me sleep peacefully at night. 
Via The Motley Fool
Topics Intellectual Property
News headline image
A Q2 2026 Playbook for Navigating Market Uncertainty ↗
Via MarketBeat
News headline image
What You Need To Know Ahead of Johnson & Johnson's Earnings Release
Johnson & Johnson is expected to announce its first-quarter results next month, and analysts are projecting a single-digit decline in its EPS. 
Via Barchart.com
Topics ETFs
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
The Fear Gauge Ascendant: VIX Hits 26 as Geopolitical Storms and 'Higher-for-Longer' Reality Grip Markets
The CBOE Volatility Index (VIX), Wall Street’s premier measure of expected stock market volatility, climbed to a reading of 26.15 this week, marking its highest sustained level in nearly two years. As... 
Via MarketMinute
Topics Derivatives Economy Stocks
News headline image
If You Only Own Tech Stocks, Jim Cramer Has a Blunt Warning for You in 2026 ↗
CNBC commentator Jim Cramer sees value in the artificial intelligence (AI) realm beyond the technology sector. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.